Every material Form 8-K Corcept Therapeutics filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Corcept Therapeutics reported third quarter 2025 revenue of $207.6 million, up from $182.5 million a year earlier, but net income fell to $19.7 million from $47.2 million as operating expenses rose to $197.4 million. The company also modified its 2025 revenue guidance to $800 million to $850 million and said it added a new specialty pharmacy on October 1 to meet demand for Korlym.
Q3 2025 revenue was $207.6 million, compared with $182.5 million in Q3 2024.
Q3 2025 net income was $19.7 million, compared with $47.2 million; diluted EPS was $0.16, compared with $0.41.
Operating expenses were $197.4 million, compared with $135.9 million, reflecting spending to prepare for launches of relacorilant.
2025 revenue guidance was modified to $800 million to $850 million; the NDA for relacorilant in hypercortisolism has a PDUFA date of December 30, 2025.
Corcept director Gillian Cannon, Ph.D., notified the board on October 6, 2025 that she will resign effective October 10, 2025, and she did not cite any disagreement with the company. She will continue as a consultant to the board under a Consulting Services Agreement through the 2026 stockholder meeting, with her outstanding stock options continuing to vest, so the change is limited in scope for shareholders.
Resignation from the board effective October 10, 2025; no disagreement with the company cited
Consulting Services Agreement runs from the effective date until the 2026 stockholder meeting
Cash fee of $5,708.33 per month under the consulting agreement
Previously awarded stock options continue to vest on their original schedules
Corcept reported second quarter 2025 revenue of $194.4 million, up from $163.8 million a year earlier, but net income was $35.1 million versus $35.5 million and diluted earnings per share fell to $0.29 from $0.32. The company modified its 2025 revenue guidance to $850 million to $900 million and said demand outpaced its specialty pharmacy vendor's capacity, which it expects to ease as a second pharmacy comes online.
Q2 2025 revenue $194.4 million vs. $163.8 million in Q2 2024
Net income $35.1 million vs. $35.5 million; diluted EPS $0.29 vs. $0.32
Selling, general and administrative expense $103.9 million vs. $66.9 million a year earlier
2025 revenue guidance modified to $850 million to $900 million; cash and investments $515.0 million at June 30, 2025
Corcept reported first quarter 2025 revenue of $157.2 million, up from $146.8 million a year earlier, but net income fell to $20.5 million and diluted earnings per share fell to $0.17 from $0.25. The company reiterated its 2025 revenue guidance of $900 million to $950 million and said a specialty pharmacy vendor's capacity limits hurt first quarter results.
Revenue was $157.2 million versus $146.8 million in first quarter 2024.
Operating expenses rose to $153.8 million from $117.3 million, with selling, general and administrative expenses at $90.7 million versus $56.3 million.
2025 revenue guidance of $900 million to $950 million was reiterated.
Cash and investments were $570.8 million at March 31, 2025, down from $603.2 million at December 31, 2024.
Corcept Therapeutics reported fourth-quarter and full-year 2024 results and gave a corporate update in a press release attached to this 8-K. Full-year 2024 revenue rose to $675.0 million from $482.4 million and full-year net income rose to $141.2 million, while fourth-quarter net income and diluted earnings per share were slightly lower than a year earlier. The company also gave 2025 revenue guidance of $900-950 million.
Q4 2024 revenue was $181.9 million, compared with $135.4 million in Q4 2023.
Q4 2024 net income was $30.7 million, or $0.26 diluted per share, versus $31.4 million, or $0.28, in Q4 2023.
Full-year 2024 net income was $141.2 million, or $1.23 diluted per share, versus $106.1 million, or $0.94, in 2023.
Cash and investments were $603.2 million at December 31, 2024; company expects ROSELLA pivotal trial data in the current quarter.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Corcept Therapeutics filing is on SEC EDGAR ↗. 8-K briefs of other companies →